Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice

Young‐Bin Oh, Min Ahn, Sang‐Myeong Lee, Hyoung‐Won Koh, Sun Hwa Lee, Suhn Hee Kim, Byung‐Hyun Park

Experimental & Molecular Medicine · 2013 · 34 citations · 34 references

DOIFull text

Open access

Concepts

Abstract

Recent studies have documented that Janus-activated kinase (JAK)–signal transducer and activator of transcription (STAT) pathway can modulate the apoptotic program in a myocardial ischemia/reperfusion (I/R) model. To date, however, limited studies have examined the role of JAK3 on myocardial I/R injury. Here, we investigated the potential effects of pharmacological JAK3 inhibition with JANEX-1 in a myocardial I/R model. Mice were subjected to 45 min of ischemia followed by varying periods of reperfusion. JANEX-1 was injected 1 h before ischemia by intraperitoneal injection. Treatment with JANEX-1 significantly decreased plasma creatine kinase and lactate dehydrogenase activities, reduced infarct size, reversed I/R-induced functional deterioration of the myocardium and reduced myocardial apoptosis. Histological analysis revealed an increase in neutrophil and macrophage infiltration within the infarcted area, which was markedly reduced by JANEX-1 treatment. In parallel, in in vitro studies where neutrophils and macrophages were treated with JANEX-1 or isolated from JAK3 knockout mice, there was an impairment in the migration potential toward interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1), respectively. Of note, however, JANEX-1 did not affect the expression of IL-8 and MCP-1 in the myocardium. The pharmacological inhibition of JAK3 might represent an effective approach to reduce inflammation-mediated apoptotic damage initiated by myocardial I/R injury. A drug that inhibits a signaling cascade of inflammatory cells improves outcomes in a mouse model of a heart inury known as myocardial reperfusion. This injury occurs when blood flow returns to oxygen-deprived tissue. Byung-Hyun Park and his colleagues at the Chonbuk National University, Korea, gave young male mice a drug, JANEX-1, which blocks a protein called Janus kinase 3 (JAK3). They then restricted blood supply to the animals' hearts for 45 minutes and subsequently allowed for varying periods of blood flow restoration. Drug treatment significantly reduced the extent of cellular damage in the heart by limiting the infiltration of macrophages and neutrophils, two important inflammatory cells. The drug did this, in part, by suppressing the migration ability of hese cells toward chemokines, immune signaling molecules that help bring macrophages and neutrophils to the injury site.

References

34